[{"id":"enasidenib","kind":"drug","name":"Enasidenib","route":"/drugs/enasidenib/","commit":"08f191a505","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for thirty more approved products","file":"src/data/spikes/aml.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Enasidenib\" }]"}]},{"id":"enasidenib","kind":"drug","name":"Enasidenib","route":"/drugs/enasidenib/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/aml.ts","type":"changed","fields":[{"field":"tldr","before":"\"The IDH2 counterpart of ivosidenib, approved in the US for relapsed disease but never approved in Europe after it failed to extend survival in a confirmatory trial.\"","after":"\"Enasidenib is the IDH2 counterpart of ivosidenib, approved in the US for relapsed disease but never approved in Europe after it failed to extend survival in a confirmatory trial.\""}]},{"id":"enasidenib","kind":"drug","name":"Enasidenib","route":"/drugs/enasidenib/","commit":"713bfbdd72","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: AML, ALL, CLL deep dives (102 new entities: trials with structured outcomes, products with dosing/toxicity/regulatory events, target","file":"src/data/spikes/aml.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"mechanismSteps"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"regulatoryEvents"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"terms"},{"field":"tags"}]}]